Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Towards Better Therapy for Resectable Lung Cancer: Metabolomics Predict Therapy Response

NCT03736993 is registered in ClinicalTrials.gov with Hasselt University as lead sponsor.

NCT NCT03736993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03736993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Towards Better Therapy for Resectable Lung Cancer: Metabolomics Predict Therapy Response
Lead sponsor
Hasselt University
Phase
Not applicable
Overall status
Completed
Start date
May 28, 2018
Completion date
December 31, 2022
Enrollment
160 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, stage iiia